LENZ Earnings Date: Mar 23, 2027 (Estimated) — LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is LENZ's next earnings date?
LENZ Therapeutics, Inc. (LENZ) is expected to report Q4 2026 earnings on Tuesday, March 23, 2027 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.93 on revenue of $5.1M.
How did LENZ do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), LENZ Therapeutics, Inc. posted EPS of -$0.99 versus the -$0.89 estimate, a miss of 10.8%. Revenue was $3.4M against a $4.2M estimate. The stock's 1-day post-earnings move was +8.7%.
How much does LENZ stock move after earnings?
LENZ beat EPS estimates in 3 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 10.5% (up or down) in the day after earnings.
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
🤖 AI Earnings Analysis
Despite VIZZ sales rising 50% sequentially and consumer marketing becoming the focus, Q3 was weak: revenue was $3M versus $4M expected and loss widened to $0.99 per share.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.89 | -0.99 | -10.84% | $3.4M | ❌ Miss | +8.72% | — | — |
| 2026-08-11 | Q2 2026 | -1.05 | -1.02 | +7.27% | $5.5M | ✅ Beat | -3.26% | -8.45% | -9.40% |
| 2026-05-11 | Q1 2026 | -1.08 | -1.32 | -22.22% | $1.9M | ❌ Miss | -20.82% | -30.93% | -34.13% |
| 2026-03-24 | Q4 2025 | -0.91 | -1.16 | -27.47% | $1.6M | ❌ Miss | -17.91% | -24.64% | -9.18% |
| 2025-11-05 | Q3 2025 | -0.68 | -0.59 | +13.24% | $12.5M | ✅ Beat | -23.46% | -5.70% | -0.53% |
| 2025-07-30 | Q2 2025 | -0.67 | -0.53 | +20.90% | $5.0M | ✅ Beat | -2.87% | -3.76% | +18.00% |
| 2025-03-19 | Q4 2024 | -0.40 | -0.46 | -15.00% | $0 | ❌ Miss | +3.06% | +2.23% | -6.66% |
| 2024-08-14 | Q2 2024 | — | -0.40 | — | $0 | — | -3.83% | -4.38% | -6.98% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $5.5M total
| Segment | Share | Revenue | YoY | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| License | 68.4% | $3.8M | — | $5.0M | $12.5M | $250K | $3.8M |
| Product | 31.6% | $1.7M | — | — | — | $1.7M | $1.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.